

## CONTENTS

### CHAPTER-I (SELF EMULSIFYING DDS)

TOPIC NO	NAME OF THE TOPIC	PAGE NO
1.0	<b>Introduction</b>	1
1.1	Definition	4
1.2	Advantages	5
1.3	Approaches of delivery systems	7
1.4	Biopharmaceutical aspects	8
1.5	Selection of drug candidate for SEDDS formulation	12
1.6	Excipients used in SEDDS/S(M)EDDS	13
1.7	Dosage form development of SEDDS	14
1.8	Formulation of SEDDS	15
1.9	Factors affecting formulation of SEDDS	16
1.10	Mechanism of self emulsification	16
1.11	Improvement of oral absorption of SEDDS	17
1.12	Characterization of SEDDS	23
1.13	Drawbacks of SEDDS	24
1.14	Advantages of solid S(M)EDDS	26
1.15	Efavirenz drug profile	27
2.0	<b>Literature survey</b>	29
3.0	<b>Aim and Objective</b>	31
4.0	<b>Materials and methods</b>	32
4.1	Materials	32
4.2	Animals	32
4.3	Methods	32
5.0	<b>Characterization of S(M)EDDS</b>	41
5.1	Dissolution studies of solid S(M)EDDS	41

5.2	Drug excipient compatibility studies	41
5.3	XRD studies	42
5.4	Microscopic studies	42
5.5	Pharmacokinetic study	42
5.6	Determination of Efavirenz in Rat plasma by LC/MS-MS method	43
5.7	Chromatographic and Mass spectroscopic conditions	47
5.8	Pharmacokinetic Data Analysis for Solid SMEDDS formulation and pure drug suspension	50
6.0	<b>Results and Discussion</b>	51
6.1	Standard graph of Efavirenz	51
6.2	Particle size reduction and distribution of Efavirenz	52
6.3	Solubility studies	54
6.4	Pseudo ternary phase diagram	55
6.5	Visual observation	56
6.6	Freeze Thawing	58
6.7	Emulsion Droplet size Analysis	58
6.8	In-vitro dissolution studies of SMEDDS	60
6.9	Oil adsorption study	62
6.10	S(M)EDDS to Solid S(M)EDDS	62
6.11	Dissolution studies of Solid and liquid S(M)EDDS	63
6.12	FT-IR studies	64
6.13	XRD studies	67
6.14	Morphological characterization by light microscope	68
6.15	In-Vivo studies	69
7.0	<b>Summary and Conclusion</b>	72